title: Inhibition of platelet aggregation with eptifibatide, bivalirudin, and heparin in patients undergoing percutaneous coronary intervention receiving clopidogrel pretreatment (The PharmacoDynamic Evaluation of Angiomax, Clopidogrel with or without INtegrilin [DEACON] study).
abstract: The present study assessed the magnitude of inhibition of platelet aggregation induced by adenosine diphosphate and thrombin receptor activating peptide achieved with unfractionated heparin, the direct thrombin inhibitor bivalirudin, and the glycoprotein IIb/IIIa inhibitor eptifibatide in patients who underwent percutaneous coronary intervention and and were treated with concomitant aspirin and clopidogrel.
authors.affiliation: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA. jorge-saucedo@ouhsc.edu
authors.forename: Jorge F
authors.initials: JF
authors.lastname: Saucedo
authors.forename: Wady
authors.initials: W
authors.lastname: Aude
authors.forename: Rebecca
authors.initials: R
authors.lastname: Pacheco
authors.forename: Brett
authors.initials: B
authors.lastname: Thorn
authors.forename: Zakaria
authors.initials: Z
authors.lastname: Matin
authors.forename: Khawaja
authors.initials: K
authors.lastname: Husain
authors.forename: Luis
authors.initials: L
authors.lastname: Garza
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000493:pharmacokinetics / Q000627:therapeutic use; D000077144:Clopidogrel; D004359:Drug Therapy, Combination; D000077542:Eptifibatide; D005260:Female; D005500:Follow-Up Studies; D006493:Heparin / Q000627:therapeutic use*; D006629:Hirudins / Q000493:pharmacokinetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000097:blood / Q000628:therapy*; D010446:Peptide Fragments / Q000493:pharmacokinetics* / Q000627:therapeutic use; D010455:Peptides / Q000493:pharmacokinetics* / Q000627:therapeutic use; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D011300:Preoperative Care / Q000379:methods; D011994:Recombinant Proteins / Q000493:pharmacokinetics / Q000627:therapeutic use; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D006629:Hirudins; D010446:Peptide Fragments; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011994:Recombinant Proteins; D006493:Heparin; D000077144:Clopidogrel; D000077542:Eptifibatide; D013988:Ticlopidine; C074619:bivalirudin